GlassScriptPhysician profile
Lauren Snower
NPI 1639459597
$15,632.07
in general payments reported to CMS, 2019-2025
47 companies · $2,456 in 2025
The $2,456 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,408 · 2020: $1,151 · 2021: $2,266 · 2022: $2,580 · 2023: $2,623 · 2024: $2,148 · 2025: $2,456.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,228.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,227.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,287.59 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $1,993.29 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,788.80 | 2019-2025 | Qulipta, Ubrelvy, Vraylar |
| Pfizer INC. | $1,190.84 | 2019-2025 | |
| Amgen INC. | $968.50 | 2019-2025 | Otezla, Repatha, Prolia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $930.17 | 2019-2025 | Jardiance, Tradjenta |
| Lilly USA, LLC | $892.74 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novartis Pharmaceuticals Corporation | $715.43 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $535.52 | 2022-2025 | |
| Amarin Pharma, INC. | $356.31 | 2019-2022 | |
| Glaxosmithkline, LLC. | $332.12 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Dexcom, INC. | $312.21 | 2021-2025 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $296.15 | 2019-2024 | Capvaxive, Gardasil 9, Gardasil |
| Astellas Pharma US INC | $267.11 | 2019-2025 | Veozah |
| Aimmune Therapeutics, INC. | $264.55 | 2024-2025 | Zenpep |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $242.34 | 2019-2023 | Xarelto |
| Sanofi-Aventis U.S. LLC | $241.65 | 2019-2023 | |
| Exact Sciences Corporation | $213.64 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $211.78 | 2019-2025 | Eliquis, Camzyos |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $209.91 | 2019-2024 | Xifaxan |
| Abbott Laboratories | $176.39 | 2019-2025 | Freestyle Libre 3 |
| Allergan, INC. | $143.70 | 2019-2020 | |
| Boston Scientific Corporation | $111.33 | 2019-2022 | |
| Xeris Pharmaceuticals, INC. | $104.04 | 2022-2024 | Gvoke Hypopen |
| Harmony Biosciences LLC | $91.82 | 2022-2023 | Wakix |
| Ferring Pharmaceuticals INC. | $90.99 | 2024 | Euflexxa |
| Ironwood Pharmaceuticals, INC | $80.16 | 2020-2022 | |
| Philips North America LLC | $56.16 | 2022-2024 | (Ak6) Vest Therapy |
| Sanofi Pasteur INC. | $52.60 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $51.85 | 2022 | |
| Sumitomo Pharma America, INC. | $39.88 | 2023 | Gemtesa |
| Recor Medical INC | $37.96 | 2024-2025 | Paradise Ultrasound Renal Denervation System, Paradise Renal Denervation System |
| Phathom Pharmaceuticals, INC. | $33.30 | 2024 | Voquezna |
| Lundbeck LLC | $33.02 | 2025 | Rexulti |
| Hikma Pharmaceuticals USA | $32.93 | 2022 | |
| Smith+Nephew, INC. | $28.73 | 2019-2020 | |
| Horizon Therapeutics Plc | $27.92 | 2021 | |
| Dynavax Technologies Corporation | $26.87 | 2024 | Heplisav-B |
| Opko Pharmaceuticals, LLC | $25.92 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $25.50 | 2022 | |
| Genzyme Corporation | $24.15 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $16.77 | 2021 | |
| Lifescan, INC. | $15.95 | 2022 | |
| Electromed, INC. | $14.72 | 2021 | |
| Cranial Technologies, INC | $14.28 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $13.16 | 2024 | Uptravi, Opsumit |
| Phadia US INC. | $11.32 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lauren Snower listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.